logo.png
Orphazyme phase 2 study of arimoclomol in Gaucher disease demonstrates marked improvements in key clinical markers
24 juin 2020 01h00 HE | ORPHAZYME A/S
Orphazyme A/SCompany announcement                                                                                      No. 36/2020                                                                     ...
logo.png
Publication of manuscript on preclinical Proof-of-Concept of arimoclomol in Gaucher disease
27 nov. 2018 08h51 HE | ORPHAZYME A/S
Orphazyme A/SInvestor news                                                                                                                                                         No....
logo.png
Enrollment of first patient in Phase II clinical trial for Gaucher disease
21 juin 2018 03h17 HE | ORPHAZYME A/S
Orphazyme A/SCompany announcement                                                                                                                   No....
Protalix BioTherapeutics to Hold Full-Year 2016 Financial Results and Corporate Update Conference Call on March 16, 2017
09 mars 2017 07h30 HE | Protalix BioTherapeutics, Inc.
CARMIEL, Israel, March 09, 2017 (GLOBE NEWSWIRE) -- Protalix BioTherapeutics, Inc. (NYSE MKT:PLX) (TASE:PLX), a biopharmaceutical company focused on the development and commercialization of...
Protalix BioTherapeutics Receives Letter Detailing Intended Purchases of Approximately $24 Million of alfataliglicerase to Treat Gaucher Patients in Brazil
14 déc. 2016 07h30 HE | Protalix BioTherapeutics, Inc.
CARMIEL, Israel, Dec. 14, 2016 (GLOBE NEWSWIRE) -- Protalix BioTherapeutics, Inc. (NYSE MKT:PLX) (TASE:PLX) (the “Company”) announced today that the Company received a letter from Fundação Oswaldo...